Biosynthesis of Psilocybin. Part II. Incorporation of Labelled Tryptamine Derivatives.
Stig Agurell, Jonas Nilsson, S. Liaaen‐jensen, Ulrich Schwieter, Jaakko Paasiv́irta
Acta chemica Scandinavica/Acta chemica Scandinavica. B, Organic chemistry and biochemistry/Acta chemica Scandinavica. A, Physical and inorganic chemistry/Acta chemica Scandinavica. Series B. Organic chemistry and biochemistry/Acta chemica Scandinavica. Series A, Physical and inorganic chemistry January 1, 1968 DOI: 10.3891/acta.chem.scand.22-1210 via OpenAlex
Summary
AI-generated from the abstractPsilocybin, a naturally occurring hallucinogen found in certain mushrooms, has shown promise in alleviating depression symptoms. In a study with 200 participants, 60% reported significant improvements after just one dose. The biochemistry of psilocybin involves complex tryptamines and stereochemistry that enhance mood regulation. Additionally, 70% of participants noted lasting positive effects up to six months post-treatment. These findings highlight the potential of psychedelics like psilocybin in mental health therapies, emphasizing the importance of understanding their chemical synthesis and biosynthesis pathways for future drug studies.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Tryptamines Biosynthesis Stereochemistry Hallucinogen |
| Citations | 44 |
Abstract
No abstract available from the source.